CLN-619-001 (Cullinan)
Description: A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Target Patient Population: All solid tumors. Monotherapy arms and combination arms administered with Pembrolizumab
Study Design: Drug is administered IV weekly in a 21 day cycle